A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.

• DOI: 10.1200/jco.2025.43.5_suppl.35
• Publication Date: 2025-02-18T14:32:12Z
• Authors: Glenn Bauman; Mohammed Rashid; Deanna L Langer; Pamela MacCrostie; Bo Green; Victor Mak; Girish S. Kulkarni; Bobby Shayegan; Laurence Klotz; Stephen E. Pautler; Antonio Finelli; Marlon Hagerty; William Luke; Andres Kohan; Vivian S Tan; Luke Lavallee; Katherine Zukotynski; Joseph Chin; Ur Metser

35 Background: PREP was initiated in Ontario to provide access and characterize performance of PSMA PET CT among men with recurrent prostate cancer after primary definitive treatment (RP or RT). Methods: Between 03/18 09/22, 4135 were accrued. Men enrolled imaged 18F-DCFPyL at 1 6 participating sites within clinical cohorts. Standardized reports delineated recurrence post management changes. Linkage provincial databases allowed estimation overall survival utilization salvage radiotherapy PET. Results: Median follow-up 1.8 years; key findings are Table 1. Significant predictors a positive scan on multi-variable analysis included: higher PSA time cohort (highest for 4). change type loco-regional) PSA. worse included (worst 4), extent metastases mixed bone/lymph/visceral extensive metastases). A significant predictor improved survival. Conclusions: The registry facilitated PET/CT high rates disease detection impact management. factors associated detected Clinical trial information: NCT03718260 . registry: Key findings. Total (n=4135) Cohort (n=255): BF 3 months from RP pN+ >0.1 2 (n=1500): following (n=1040): RPand adjuvant RT 4 (n=263): while hormone therapy 5 (n=176): Therapy Oligo-metastases prior (n=901): Age (IQR) 71.0 (66.0–76.0) 66.0 (61.0–70.0) 70.0 (65.0–74.0) 72.0 (67.0–76.0) 74.0 (69.0–79.0) 73.0 (66.0–77.0) 75.0 (70.0–79.0) (ng/mL) 1.3 (0.3–4.0) 0.7 (0.2–2.5) 0.3 (0.2–1.0) 1.1 (0.5–2.7) 3.5 (1.6–7.2) 2.4 (1.0–5.3) 4.4 (3.1–7.4) PET: Negative Findings 1216 (29.4) 84 - 88 (32.9 34.5)* 749 (49.9) 258 (24.8) 19 (7.2) 18 22 (10.2 12.5)* (9.3) Locoregional Recurrence 1377 (33.3) 95 (37.3) 471 (31.4) 295 (28.4) 63 (24.0) 34 (19.3) 419 (46.5) Oligo-Metastatic (≤5 metastases) 1021 (24.7) 45 (17.6) 224 (14.9) 354 (34.0) 111 (42.2) 70 (39.8) 217 (24.1) Extensive Metastases 521 (12.6) 29 (11.4) 56 (3.7) 133 (12.8) (26.6) 52 (29.5) 181 (20.1) Change 2070 (50.1) 135 (52.9) 585 (39.0) 552 (53.1) 152 (57.8) 99 (56.3) 547 (60.7) Radiotherapy 1729 (41.8) 165 (64.7) 866 (57.7) 346 (33.5) 49 (27.8) 215 (23.9) Died during period 138 (3.3) (0.4 2.0)* (1.2) 30 (2.9) (13.3) 8 -12 (4.5 6.8)* 44 (4.9) BF: Biochemical Failure; RP: Radical Prostatectomy; RT: Radiotherapy; IQR: Interquartile Range. *Small cell size.